Ex­clu­sive: Sanofi's CEO Paul Hud­son talks pipeline, M&A, in­sulin hear­ings and Dupix­ent

Sanofi CEO Paul Hud­son be­lieves 2023 will be one of the “most im­por­tant years in the com­pa­ny’s his­to­ry.” The French phar­ma gi­ant is rid­ing on the suc­cess of Dupix­ent, with pos­i­tive da­ta for COPD pa­tients, while bid­ding good­bye to its last ma­jor patent ex­piry for sev­er­al more years.

In an ex­clu­sive in­ter­view with End­points News, Hud­son talked about the com­pa­ny’s pipeline, whether it was in­volved in bid­ding for Seagen, how an­titrust ac­tions in the US will af­fect fu­ture deal­mak­ing, Con­gress’ in­sulin hear­ings, GLP-1 drugs, and more. (For our full sto­ry on the Dupix­ent da­ta, click here.)

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER